<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37298420</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immunopathogenesis and Novel Therapeutics Strategies of Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9470</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24119470</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus is a chronic connective tissue disease of unknown origin and unpredictable course [...].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kotyla</LastName><ForeName>Przemys&#x142;aw</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8376-6527</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olesi&#x144;ska</LastName><ForeName>Marzena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3028-1061</Identifier><AffiliationInfo><Affiliation>Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003240" MajorTopicYN="Y">Connective Tissue Diseases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37298420</ArticleId><ArticleId IdType="pmc">PMC10253874</ArticleId><ArticleId IdType="doi">10.3390/ijms24119470</ArticleId><ArticleId IdType="pii">ijms24119470</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hermann V., Batalov A., Smakotina S., Juif P.E., Cornelisse P. First use of cenerimod, a selective s1p(1) receptor modulator, for the treatment of sle: A double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci. Med. 2019;6:e000354. doi: 10.1136/lupus-2019-000354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000354</ArticleId><ArticleId IdType="pmc">PMC6861098</ArticleId><ArticleId IdType="pubmed">31798918</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J., Li M., Zhang X., Wang Q., Zhao J., Tian Z., Wei W., Zuo X., Zhang M., Zhu P. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: Cstar-pah cohort study. Eur. Respir. J. 2019;53:1800081. doi: 10.1183/13993003.00081-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00081-2018</ArticleId><ArticleId IdType="pubmed">30635295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-J., Hsu H.-C., Ho W.-J., Chang G.-J., Pang J.-H.S., Chen W.-J., Huang C.-C., Lai Y.-J. Cathepsin s promotes the development of pulmonary arterial hypertension. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2019;317:L1&#x2013;L13. doi: 10.1152/ajplung.00530.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00530.2018</ArticleId><ArticleId IdType="pubmed">31017016</ArticleId></ArticleIdList></Reference><Reference><Citation>Szab&#xf3; K., J&#xe1;mbor I., P&#xe1;zm&#xe1;ndi K., Nagy N., Papp G., Tarr T. Altered circulating follicular t helper cell subsets and follicular t regulatory cells are indicators of a derailed b cell response in lupus, which could be modified by targeting il-21r. Int. J. Mol. Sci. 2022;23:12209. doi: 10.3390/ijms232012209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012209</ArticleId><ArticleId IdType="pmc">PMC9602506</ArticleId><ArticleId IdType="pubmed">36293075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuca-Warnawin E., Pleba&#x144;czyk M., Ciechomska M., Olesi&#x144;ska M., Szcz&#x119;sny P., Kontny E. Impact of adipose-derived mesenchymal stem cells (ascs) of rheumatic disease patients on t helper cell differentiation. Int. J. Mol. Sci. 2022;23:5317. doi: 10.3390/ijms23105317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23105317</ArticleId><ArticleId IdType="pmc">PMC9140468</ArticleId><ArticleId IdType="pubmed">35628127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy M., Tummala R., Streicher K., Nogueira da Costa A., Brohawn P.Z. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int. J. Mol. Sci. 2021;22:11286. doi: 10.3390/ijms222011286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011286</ArticleId><ArticleId IdType="pmc">PMC8540355</ArticleId><ArticleId IdType="pubmed">34681945</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante B., Mercuri S., Dello Strologo A., Franzin R., Catalano V., Troise D., Cataldo E., Pontrelli P., Alfieri C., Binda V., et al. Unraveling the link between interferon-&amp;alpha; and systemic lupus erythematosus: From the molecular mechanisms to target therapies. Int. J. Mol. Sci. 2022;23:15998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9783870</ArticleId><ArticleId IdType="pubmed">36555640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubo&#x144; W., Lubo&#x144; M., Kotyla P., Mrukwa-Kominek E. Understanding ocular findings and manifestations of systemic lupus erythematosus: Update review of the literature. Int. J. Mol. Sci. 2022;23:12264. doi: 10.3390/ijms232012264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012264</ArticleId><ArticleId IdType="pmc">PMC9603180</ArticleId><ArticleId IdType="pubmed">36293119</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>